Antibodies targeted against pathological processes in one neurodegenerative disease might be effective in other diseases, including Alzheimer’s, according to the Swiss biotech AC Immune SA which is beefing up its early discovery pipeline with such “next-generation” antibodies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?